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Abstract 
Background 
The features of the Hypertrophic Cardiomyopathy (HCM) ECG make it a challenge for 
Subcutaneous ICD (S-ICD) screening. We aimed to investigate the causes of screening 
failure at rest and on exercise to inform optimal S-ICD ECG vector development. 
 
Methods and Results 
131 HCM patients (age:50 ±16 years ,92M;39F) with ≧1HCM risk factor for sudden death 
underwent S-ICD ECG screening at rest and on exercise. Fifty patients (38%) were ineligible 
for S-ICD due to screening failure in every lead vector - 33 (66%) failed in the supine 
position; 12 patients (24%) failed in the standing position and 5 (10%) on exercise. In 
patients who could exercise and passed screening at rest, 31(44%) had one vector safety, 
16(23%) had two vector safety and 24(33%) had three vector safety. Increased R:T-wave 
ratio in the S-ICD screening ECG (OR 4.0, CI 3.0-5.3, p<0.001) was associated with 
screening failure, while R/T ratio <3 in Avf (OR 0.3, CI 0.12-0.69, p=0.006) and increasing 
age (OR0.97, CI 0.95-0.99, p=0.03) were associated with reduced screening failure. ESC 
risk score was higher in those failing screening (Risk score 5.5% (IQR 3.2-8.7) in failed vs 
4.5% (IQR 2.9-7.4) in passed; p=0.04). 
 
Conclusions 
HCM patients have a significant incidence of screening failure which is determined primarily 
by the increased R:T ratio on the screening ECG and lead aVF. High-risk patients have an 
increased screening failure rate. Optimization of sensing algorithms is required in order to 
ensure that the highest risk HCM patients can benefit from S-ICD implantation. 
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Background 
 
The implantable cardioverter-defibrilator (ICD) has been a groundbreaking advance in the 
prevention of sudden cardiac death (SCD)1. However, the complications of current 
transvenous implantable devices, such as infection and lead failure are a significant and 
expanding problem, particularly with the improved survival of younger recipients2-9. In 
patients with hypertrophic cardiomyopathy (HCM), where devices are frequently implanted 
for primary prevention in young individuals, complication rates are often unacceptably 
high10,11. The advent of the Subcutaneous Internal Cardiac Defibrillator (S-ICD), represents 
an important alternative avoiding intravascular leads12-14 as reflected in the IDE13 study and 
EFFORTLESS 15 registries where young patients with inherited channelopathies or non-
ischemic cardiomyopathy including HCM were implanted16 . 
 
The S-ICD continuously senses the surface ECG from three bi-polar vectors derived from 
its subcutaneous poles and ICD generator positions (Figure 1A). The QRS and T-wave 
morphology are templated within the device and this is used in combination with internal 
algorithms to differentiate between ventricular and supraventricular arrhythmias17. Thus the 
quality of the ECG recorded from the surface, as well as the amplitude and ratio of the T-
wave and QRS complexes are a critical element in the screening process of eligibility for the 
device. Previous studies have suggested that up to 7.4% of patients fail screening and that 
hypertrophic cardiomyopathy (HCM) may increase the odds of screening failure due to large 
amplitude T-wave and QRS complexes in these patients18. However, either limited numbers 
of patients with HCM have been recruited in previous studies18 or high risk HCM patients 
likely to represent those clinically considered for ICD have been underrepresented18,. 
Additionally systematic screening on exercise, when QRS and T-wave morphology 
frequently change has not been performed systematically19,20.This study aimed to assess 
the proportion of HCM patients without pacing indications and ≧1 of the AHA guideline21,22 
risk factors for sudden cardiac death (SCD) were eligible for the S-ICD on the basis of 
screening at rest and on exercise.  
 
 
Methods 
 
Study Population 
 
One-hundred-and-thirty-one consecutive patients with HCM and ≧1 risk factor for SCD were 
screened for eligibility for S-ICD, during their outpatient clinic visit, between July 2014 and 
September 2015. Three patients were under investigation for suspected HCM with a family 
history of sudden cardiac death. The cohort did not include any patients being clinically 
evaluated for S-ICD, to avoid selection bias. Patients were excluded if they were <20 or >70 
years of age or had sustained monomorphic VT. Patients with a pre-existing ICD were 
included and 19 of these were intermittently paced. The study was approved by our local 
research ethics committee, and all patients provided informed consent. 
 
 
 
 
 
 
 
Screening Protocol 
 
ECG screening was undertaken by placing ECG electrodes on the xiphoid, sterno-
manubrium junction, normal lead position V6 and the right lower abdomen (ground 
electrode), to simulate the 3 sensing vectors of the S-ICD(Figure 1A). A 30-second ECG 
was recorded in the supine and standing positions as well as standing step exercise to a 
heart rate of 120bpm. The 3-lead ECG’s were recorded on the Boston Scientific Zoom 
programmer (Boston Scientific. inc), at a paper speed of 25mm/s with the ECG gain set to 
5, 10 and/or 20 mm/mV. The ECG template screening tool (Figure 1B&C), as provided by 
Boston Scientific was used to assess whether each of the 3 vectors was suitable for the S-
ICD. A patient was considered suitable if at least 1 vector passed in all three screening 
positions (supine, standing and exercise). Screening analysis was performed by KP & NS, 
There were disparities in 3 cases, where PL was the adjudicator. Alternative screening 
positions were not assessed as part of the protocol, as the study was designed as a 
prospective assessment of standard screening methodology and there were time 
constraints for patients in clinic.  
 
 
Data Collection 
 
Patient demographic data were collected from the medical records. Left ventricular ejection 
fraction (LVEF) was estimated using either visual methods or Simpsons bi-plane method by 
the hospital echocardiography department. 12-Lead ECG parameters were collected from 
the most recent supine surface ECG. All 12-Lead ECG data are expressed with the machine 
calibrated to 10mm/mV, while 3-Lead ECG parameters are expressed in relation to a 
calibration of 5mm/mV. 
 Statistical Analysis  
 
Parametric data are expressed as mean and standard deviation and analyzed using a 
Student's t-test. Non-parametric data are expressed as median and interquartile range 
(IQR), and analyzed using Mann Whitney U-test. Categorical data are expressed as 
percentages and analyzed using chi-square test. Clinical predictors of failure of screening 
protocol were analyzed using multivariable analysis. Factors associated with increased 
screening failure or success at a P-value of <0.05 were input into the model. Where there 
was significant pairwise correlation between factors; correlation of >0.8; these were 
eliminated and all remaining variables put into a manual backwards elimination model. P-
values <0.05 were considered significant. Postural variation between vectors associated 
with passing or failing screening were assessed using logistic regression. Three-lead-ECG 
factors associated with screening failure were analyzed by logistic regression. Statistical 
analysis was performed using R statistical computing software (Version 3.2.2) 23. 
 
 
 
 
 
 
 
 
 
Results 
 
Baseline Characteristics 
One-hundred-and-thirty-one consecutive patients with HCM and ≧1 risk factor for sudden 
death22 were screened in our outpatient department. Clinical characteristics of the patients 
(70% male, mean age : 50 ±16 years) are shown in Table 1. Eleven patients where in atrial 
fibrillation at the time of screening. In total 51(39%) patients had a pre-existing ICD, 45(34%) 
for primary prevention and 6(5%) for secondary prevention. 10 patients were unable to 
exercise, either due to their clinical condition or their request not to exercise. Fourteen 
patients (11%) had a previous myomectomy and 4 patients (3%) had a previous alcohol 
septal ablation. Forty-six patients(35%) were on no medication.Table 1). 
 
Eighty one patients (62%) had ≥2 conventional risk factors for SCD21,22. Based on the 
European Society of Cardiology (ESC) risk assessment score24,25, 53 patients (41%) were 
high risk (5-year risk ≥6%), 24 patients (18%) were intermediate risk (5-year risk of 4%≥ & 
<6%), and 54 patients (41%) were low risk (5-year risk <4%).  
 
 
Eligibility for S-ICD based on 3-Lead ECG Vector screening 
 
In total 50 patients (38%) were ineligible for S-ICD due to screening failure on the basis of 
failure in every S-ICD lead vector (Table 2.). Figure 2A shows the percentage of all patients 
passing or failing S-ICD screening in the supine position, with additional failures during 
standing and exercise (Figure 2B &C) as a percentage of total patients screened. Of the 50 
patients that failed screening- 33 (66%) failed screening in the supine position; a further 12 
patients (24%) failed screening in the standing position and 5 patients (10%) on exercise. 
 
Of the patients that passed screening in the supine position (Figure 2D), 47(48%) had one 
vector safety, 28(29%) had two vector safety and 23(23%) had three vector safety. In 
patients who passed screening in the standing position (Figure 2E), 39(45%) had one vector 
safety, 29(34%) had two vector safety and 18(21%) had three vector safety. Finally 10 
patients who passed screening in the supine and standing positions were unable to exercise 
due to mobility issues. Thus in the 71 patients who were able to exercise and passed all 
screening (Figure 2F), 31(44%) had one vector safety, 16(22%) had two vector safety and 
24(34%) had three vector safety. 
 
Figure 2G-I. shows the number of patients passing or failing in the supine, standing and 
exercise positions, in relation to their screening vector. Logistic regression suggested that 
the primary vector was statistically more likely to fail screening in the supine (Fail 62%, Pass 
38%, OR 1.6, CI 1.1-2.6, P=0.03) and standing positions (Fail 59%, Pass 41%, OR 2.2, CI 
1.2-4.0, P=0.007), while the alternate vector was more likely to pass in the standing (Fail 
39%, Pass 61%, OR 1.5, CI 1.05-2.4, P=0.03) and during exercise (Fail 21%, Pass 79%, 
OR 1.9, CI 1.2-8, P=<0.001).  
 
Twenty-two patients (44%) failed due to a large amplitude QRS complex for the template, 
17 (34%) due to a T-wave morphology not fitting the template, 10 (20%) failed because of a 
broad QRS for the template, and 1 (2%) patient had frequent ectopy as a cause for screening 
failure. The differences in maximal QRS deflection, QRS width, T-wave amplitude and R/T 
ratio between passing and failing screening on the 3-Lead ECG calibrated to 5mm/mV are 
shown in Figure 3. Logistic regression demonstrated an increased R/T-wave ratio in patients 
that failed screening (OR 4.0, CI 3.0-5.3, p<0.001). While patients that passed vector 
screening in HCM had a broader QRS (OR 1.02, CI 1.01-1.03, p<0.001) and larger 
amplitude T-waves (OR 1.6, CI 1.5-1.8, p<0.001). Patients who failed screening showed no 
significant difference in QRS amplitude at the chosen significance level, with a median 
maximal deflection 9mm (IQR 6-12) vs. 7mm (IQR 4-14), (OR 1.01, CI 0.98-1.03, p=0.326). 
 
 
 
Clinical and 12-Lead ECG Factors Influencing Screening Pass or Failure 
 
Clinical: 
Factors associated with screening success or failures are shown in Table 2. There was no 
gender difference in screening failure rate, 34 males (36% of all males) and 16 females 
(41% of all females) failed screening; p = 0.81. Younger patients were more likely to fail than 
older patients. The mean age of patients passing was 54-years vs 46-years for patients 
failing p = 0.006. Patient weight (n=127) was not associated with an increased screening 
failure rate (p=0.35). Conventional risk factors were not associated with a failure of 
screening, however patients with a family history of SCD appeared to show an increase rate 
of screening failure vs success (62% vs 31 % respectively, p<0.001). Posterior wall 
thickness was not associated with an increased failure rate (p=0.11). Patients with pre-
existing ICD’s were not more likely to fail screening p = 0.7. Of the patients who were 
intermittently paced 16 (84%) passed screening. Maximal LVOT velocity was greater in 
patients who passed vs failed screening (22mmHg vs 10mmHg respectively, p=0.009) 
 
Surface 12 lead ECG:  
Surface ECG characteristics that were significantly different between patients who passed 
and failed screening are shown in Table 2. QRS duration (114 milliseconds vs 100 
milliseconds; p=0.004) and QTc interval (455 milliseconds vs 438; p=0.02) were found to be 
significantly different between patients passing and failing respectively. T-wave factors 
associated with a screening pass or fail were maximal T-wave amplitude (6mm vs 5mm; 
p=0.03) in any lead, maximal T-wave amplitude in lead I (2mm vs 1.5mm; p=0.005) and 
maximal T-wave amplitude in Lead avF (2mm vs 1.5mm; p=0.03). An increased ratio of the 
R-wave to T wave in lead avF (2.5 vs 5; p=0.003) was associated with a risk of screening 
failure, while a low ratio of R/T in avF was associated with an increased likelihood of passing 
screening (53% vs  22%; p=<0.001).  
 
Patient risk: 
ESC 5 year risk was significantly higher in patients who failed screening (5.5%/5y vs 
4.5%/5y, p=0.04). Patients deemed high risk by the ECS 5 year risk score24, accounted for 
a greater proportion of screening failures (27 of 50 patients (54%); p=0.02), as shown in 
Table 2. There was also a trend towards patients with ≥2 conventional risk factors21,22 failing 
screening p=0.08.  Patients at low risk24 showed a trend towards increased screening 
success (p=0.06).  
 
Screening failure: 
Variables that differed significantly (p=<0.05) between screening pass or failure were 
assessed for pairwise correlation between each other.  Variables without correlation to each 
other were then all input into a manual backwards elimination multivariable logistic 
regression mode. The final model variables are seen in Table 3. Multivariable logistic 
regression analysis demonstrated that R/T <3 in lead AVF, was associated with lower odds 
of screening failure (OR 0.3, 95%CI 0.12-0.69; p = 0.006), and increasing age per year made 
screening failure less likely (OR 0.3, 95%CI 0.95-0.99; p = 0.03). 
 
 
 
 
Screening vector screening safety in relation to ESC Risk profile 
  
As shown in Table 2, 50-patients (38%) failed ECG screening using the one-vector safety 
rule. Using the more stringent 2-vector safety rule 93 patients (71%) failed screening for the 
device. Supplemental Figure 1. shows that the screening failure with one vector and two 
vector safety. Using one vector safety, screening failure increased with increasing ESC-Risk 
score, from low (28%), through to intermediate (33%) and high risk (51%). Using the 
recommended 2-vector safety, 67% of low risk patients failed, 71% of intermediate risk 
patients failed and 76% of high risk patients failed screening.   
 
 
 
 
 
 
 
 
 
Discussion 
The S-ICD is a groundbreaking and important clinical tool in the management of patients at 
risk of ventricular arrhythmia. Its use has now become standard practice particularly in young 
patients with inherited cardiac syndromes 15,16,26,27. This is the first systematic study to look 
specifically at S-ICD eligibility of HCM patients with one or more conventional AHA risk 
factors for SCD at rest and on exercise in the limited standard screening positions. Although 
the majority of patients (62%) with HCM passed screening assessment for the device, 38% 
of patients failed screening. ESC 5-year Risk was associated with increased screening 
failure rate (5.5%/5yr vs 4.5%/5yr, p=0.04) and patients deemed higher risk were more likely 
to fail screening, accounting for 54% of failed screenings (p=0.02). On multivariate analysis 
an R/T ratio of <3 in aVF (OR 0.3, p=0.006) and increasing age per year (OR 0.97, p=0.03) 
were associated with lower occurrence of screening failure.  Of the patients who passed 
screening for the device 55% had >1 vector safety while 45% of patients passed with one 
vector safety using conventional supine and standing screening, with similar findings (41%) 
on exercising the patients. Though the majority of failures occurred in the supine (66%) and 
standing positions (24%), 10% of total screening failures occurred on exercise. The primary 
vector was the most likely to fail screening (Figure 2).  
 
 
 
Eligibility For S-ICD 
 
Eligibility for S-ICD based on pre-implant ECG screening is reported to be in the range of 
80-95%18,28,29. Previous studies18 in a mixed SCD risk cohort have suggested that HCM is an 
independent risk factor for S-ICD screening failure. Two previous studies have specifically 
assessed screening failure in patients with HCM19,20. Francia et al. 20 investigated screening 
failure in 47 patients and found a failure rate of 7% using the standard supine and standing 
screening method, and 15% in patients who were exercised. Recently Maurizi et al.19 
screened a cohort of 165 patients with HCM, and found a 16% screening failure rate, 
however, they did not screen these patients on exercise, where T wave oversensing may 
be a particular problem30. Our study shows the highest screening failure rate (38%) in a 
cohort of higher risk HCM patients (41% High risk & 18% Intermediate ESC Score Risk), 
who are more representative of patients being considered for ICD implantation in standard 
clinical practice. It is interesting to note in the study of Maurizi et al.19 that in their small cohort 
(n=22, 13% of total cohort) of “high-risk” patients, 36% of patients failed screening with at 
least one-vector safety. Thus our study shows comparable results of screening failure in 
patients who are most likely to be clinically considered for an ICD.  
 
 
Underlying Reasons for HCM ECG Screening Failure 
Patients with HCM exhibit progressive remodeling of the ventricles over time with dynamic 
changes on surface ECG31-33. These changes are critical to the applicability of S-ICD 
technology as the device is currently entirely dependent on the surface ECG to determine 
eligebility. It has previously been described that the severity of 12-lead ECG abnormalities, 
particularly T-wave abnormalities, QRS-duration and LV hypertrophy, correlate with the 
severity and evolution of the structural phenotype in HCM34. Additionally, the severity of the 
ECG phenotype correlates with outcome35, in that those patients with a phenotypically 
normal ECG appear to have a low mortality compared to those with significant ECG 
abnormalities35. This may explain the higher screening template failure rate in our higher risk 
cohort, as they may have been more likely to present with an abnormal ECG that is outside 
the bounds of the current screening template. Our study therefore has major implications 
regarding the need for careful screening of patients who are at higher risk of SCD and 
require an ICD according to current clinical guidelines, to ensure they have adequate 
sensing safety. Additionally, it highlights the importance of careful monitoring of the patients 
to ensure that the evolution in ECG morphology with disease progression does not alter 
device sensing. This is particularly relevant in lower risk HCM cohorts where screening 
failure may be as low as the 13% reported by Mauriziet al. 19 and clinicians may be more 
inclined to implant an S-ICD, given the lower risk of long term complications. Such patients 
will benefit from the avoidance of tranvenous lead implantation by monitoring the ECG on 
follow-up and if significant changes develop, the S-ICD can be optimized to avoid any 
inappropriate therapies.  
 
 
 
 
3-Lead S-ICD Vector Template Screening 
 
Our study shows that using standard recommended supine and standing screening in only 
the left sternal position, 45% of the total patients screened passed with one vector safety. 
Current ESC guidelines24 recommend ≥2 vector safety on screening before implanting the 
S-ICD in HCM. Applying this more stringent cut-off would increase the failure rate of 
screening to 71% (n=93), which is similar to that described by Maurizi et al.19, where 44% of 
the entire cohort of patients and 72% of the high-risk cohort of patients were ineligible based 
on these criteria. Additionally, 10% of total screening failures occurred during exercise, 
which reflects the importance of screening patients on exercise where T-wave over-sensing 
is a known problem20,30. 
We noted that the primary vector was statistically more likely to fail screening while the 
alternate vector was more likely to pass (Figure 2.). Francia et al. 20 also recently reported 
that the alternate sensing vector was the most compatible in their cohort of HCM patients 
with a pre-existing ICD. This is contrary to the findings in general population screening18 
where the alternate vector is the most likely to fail screening. In the S-ICD, the alternate 
vector is orientated at 90° to the frontal plane of the chest, while the primary vector is at 0°, 
with the secondary vector in between the two. In HCM, the cardiac frontal axis is 
progressively shifted leftward due to left ventricular hypertrophy32 33. This potentially shifts 
the major depolarizing and repolarizing vectors parallel to the primary screening vector in 
HCM patients making large QRS and T-wave complexes more likely to cause screening 
failure. This is particularly notable during standing and exercise where the alternate vector 
was statistically more likely to pass, perhaps because of the effect of changing position of 
the heart with posture in realigning the major depolarizing and repolarizing vectors more 
perpendicular to the alternate screening vector, making T-wave oversensing and problems 
with large amplitude QRS complexes less likely. It also explains the finding that in patients 
with HCM patients, right sternal lead placement appears to have no significant effect in 
improving screening failure rate20, as this alters the alternate vector but does little to 
influence the primary vector which appears to be the predominant sensing vector in 
screening failure.  
 
The S-ICD is designed for optimal lead and generator position to achieve the lowest possible 
DFT and appropriate sensing vectors13. The sternal position of the lead and lateral siting of 
the can mean that only the primary vector is deployed maximally orthogonal to the cardiac 
axis with the alternate vector being the least orthogonal in patients with structurally normal 
hearts. In HCM there is a leftward shift of the cardiac axis32 33, and the opposite is true. This 
is evident in the screening ECG as demonstrated in this study and others18,19  
 
The major cause for screening failure was large amplitude QRS complexes. This is reflected 
in the finding of larger maximal QRS amplitude in patients that failed, and a larger R/T ratio 
(Figure 3.). The finding of T-waves not fitting the screening template as a second major 
cause for screening failure, despite such patients having smaller maximal T-wave amplitude, 
suggests that the morphology of the T-wave and not amplitude alone determine screening 
failure. It is interesting to note that in the study of Mauriziet al. 19, T-wave inversion in the 12-
Lead ECG was associated with screening failure. This warrants further investigation, 
particularly in relation to the design of the screening template. 
 
Clinical Characteristics of Failure 
 
The major clinical factor associated with an increased risk of screening failure was the 
presence of an increased ESC 5-year Risk score (median 5.5%/5yr in failed patients vs 
4.5%/5yr in pass patients; p=0.04). High risk patients accounted for 54% of failed screening 
patients (p=0.02). Using the 1-vector and 2-vector safety rule, the majority of patients who 
passed S-ICD screening were from the low risk cohort, with screening failure increasing with 
ESC-Risk score (Figure 4.). This has important implications because 45% of patients who 
would be considered for an ICD based on the ESC risk score24,25 and 44% of patients based 
on the AHA guidelines22, would potentially be ineligible for the device employing a one vector 
safety rule. It is well known that lower risk patients appear to display a more normal 
phenotypic ECG35, while increasing phenotypic expression of HCM on cardiac MRI has been 
associated with progressive severity of ECG abnormalities34. It is interesting to note that 
patients that passed screening were older, and this is reflected in the multivariable analysis 
where increasing age was associated with lower screening failure rate. This may reflect the 
natural history of the ECG in HCM where R wave amplitude in aVL & septal leads have been 
reported to decline over time31,32, thus making potential screening failure due to large voltage 
QRS complexes less likely. An R/T ratio <3 in aVF was associated with a lower screening 
failure rate, highlighting this lead as a potential surrogate marker of screening template ECG 
failure, due to tall R-waves. This is in keeping with our finding of R/T ratio being associated 
with screening failure in the 3-lead screening ECG.   
 
 
Future Directions.  
 
 
Screening failure could be improved by filtering of R wave and T wave amplitude in the 
device to account for features of the HCM ECG, such that the current ECG template 
employed can be modified to increase the ECG screening success rate. Identical band pass 
filtering as employed by the implanted S-ICD is due to be introduced in an automated 
screening tool as opposed to the current manual template which coupled with the 
SMARTPASS algorithm to prevent T wave oversensing may help reduce screening failure. 
This will need to be formally addressed in future studies. Alternatively utilizing a tailored 
floating bipole away from the heart implanted at a site of optimal R wave sensing or 
integrating signals from the 3 vectors to achieve an optimal R:T wave ratio as a summation 
of sensed surface ECG data could be considered. This would enable the minimization of 
large amplitude R waves and the subtraction of large T waves avoiding the need to implant 
additional hardware that has to communicate with the generator. A move towards bespoke 
and remote sensing electrode positions which are patient specific and allow the sensing field 
to be independent of the shock field could prove an advantage in such patients. Ultimately, 
potential screening/sensing problems could be solved with leadless sensors/pacing 
electrodes that would ensure endocardial R-wave sensing in combination with the S-ICD. 
An additional atrial sensor could further optimize the discrimination between SVT and VT.  
 
 
Limitations 
Screening was performed at rest and exercise with no assessment of right sided lead 
positioning, central sternal or posterior S-ICD generator placement. This may have resulted 
in the higher screening failure rate reported in this study. However, a recent study reported 
that right sided lead placement did not significantly increase screening success rate in HCM 
patients20. We were also limited to exercising the patients to a maximal heart rate of 120bpm 
(for ethical safety reasons), whereas standard treadmill testing with exercise to maximal 
heart rate as is routinely performed in our institution, may have further altered failure rate of 
patients on exercise. Additionally, we only report failure of screening patients for the S-ICD, 
no published data exist regarding the correlation between the screening ECG template and 
sensing within the implanted S-ICD itself where there are differences in the S-ICD sensing 
algorthms which the manual ECG template alone does not account for.  
  
 
Conclusion 
 
The S-ICD has been a groundbreaking and important leap forward in the management of 
patients with risk of ventricular arrhythmia and its applicability is ever expanding 26  Although 
the majority of patients in our cohort of patients with HCM and ≥1 indication for ICD22 passed 
based on >1 vector safety on surface ECG screening, 38% of patients were ineligible for the 
S-ICD with one vector safety, and 71% were ineligible with ≥2 vector safety as 
recommended in the ESC guidelines24 based only on standard screening methodology with 
left parasternal sensing. The median ESC risk score was higher in patients who failed 
screening, while 10% of total failures occurred on exercise.  This highlights the need for 
careful screening and selection of S-ICD candidates with HCM, including consideration of 
alternative screening positions. This should not deter from implanting devices in HCM 
patients as in HCM patients who pass screening for S-ICD as the device has an excellent 
safety and efficacy profile16. New and more advanced screening algorithms are required to 
make this important device available to a wider population of with unusual ECG 
morphologies. 
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Table 1. Baseline Characteristics 
Clinical Characteristics  
Male sex, n (%) 92(70%) 
Age in years (mean) 51±16 
Weight in kg (median) 82 (IQR 70-93) 
ICD  
      Primary Prevention, n (%) 45(34%) 
      Secondary Prevention, n(%) 6(5%) 
LVEF (median) 65 (IQR 60-70) 
LA size in mm (median) 45 (IQR 41-51) 
Max Wall Thickness in mm (median) 17 (IQR 15-20) 
Posterior Wall Thickness in mm (median) 10 (IQR 9-11) 
Peak LVOT gradient in mmHg (median) 16 (IQR 5-61) 
Risk Factors  
     LVOT obstruction, n (%) 52 (40%) 
     Family History SD, n (%) 56(43%) 
     Syncope, n (%) 44(34%) 
     NSVT, n (%) 74(56%) 
     Max Wall Thickness ≧30 mm, n (%) 3(1.5%) 
     Altered BP response to Exercise, n(%) 61(47%) 
12-Lead ECG Characteristics  
     PR Interval in milliseconds (median) 172 (IQR 155-192) 
     QRS duration in milliseconds (median) 108 (IQR 100-129) 
     QT interval in milliseconds (median) 447 (IQR 427-477) 
ESC 5 Year Risk  
     High Risk n(%) 53(41%) 
     Intermediate Risk n(%)      24(18%) 
     Low Risk n(%) 54(41%) 
Conventional Risk Factors ≥2 81(62%) 
Anti-Arrhythmic medications, n(%)  
     Beat Blocker 46(35%) 
Clinical Characteristics  
     Calcium Channel Antagonist     15(11%) 
     Beta Blocker + Calcium Channel Antagonist     5(4%) 
     Beta Blocker + Disopyramide 3(2%) 
     Beta Blocker + Amiodarone 2(1.5%) 
     Calcium Channel Antagonist + Amiodarone 2(1.5%) 
     Disopyramide 2(1.5%) 
     Dronedarone 1(0.8%) 
ICD = implantable cardiac defibrillator; LVEF = left ventricular ejection fraction; LA = left atrium; LVOT = left 
ventricular outflow tract; NSVT = non sustained ventricular tachycardia  
 
 
 
Table 2. Clinical Characteristics of Patients Passing vs Failing S-ICD screening 
  Pass (N = 81)  Fail (N = 50 ) P-Value 
Male Sex, n(%) 58(72%) 34(68%) 0.81 
Age in years (mean) 54±16 46±16 0.006 
Weight in kg (median) 82 (IQR 70-98) 82 (IQR 69-88) 0.35 
ICD 30(37%) 21(42%) 0.7 
Max Wall Thickness in mm (median) 18 (IQR 15-20) 16 (IQR 13-20) 0.11 
Posterior Wall Thickness in mm (median) 10 (IQR 9-11) 9 (IQR 8-10) 0.11 
Syncope, n (%) 24(30%) 20(40%) 0.3 
Family History SD, n (%) 25(31%) 31(62%) <0.001 
NSVT, n (%) 44(54%) 30(59%) 0.65 
Altered BP response to Exercise, n(%) 40(49%) 21(42%) 0.52 
LA Size in mm (median) 45 (IQR 41-50) 45 (IQR 40-51) 0.83 
LVEF (median) 65 (IQR 60-70) 65 (IQR 60-70) 0.47 
Max LVOT velocity (median) 22 (IQR 6-80) 10 (IQR 4-32) 0.009 
12-lead ECG Factors     
       PR interval in milliseconds (median) 173 (IQR 157-193) 171(IQR 154-192) 0.74 
       QRS duration in milliseconds (median) 114 (IQR 100-160) 100 (IQR 94-120) 0.004 
       QTc interval in milliseconds (median) 455(IQR 430-489) 438(IQR 420-464) 0.02 
  Pass (N = 81)  Fail (N = 50 ) P-Value 
QRS Amplitude Factors (mm)    
       Maximal S Wave Any Lead (median) 23(IQR 17-30) 20 (IQR 17-25) 0.07 
       Maximal R-Wave Any Lead (median) 14 (IQR 11-25) 15 (IQR 11-17) 0.35 
       Max R-Wave Lead I (median) 8 (IQR 5-12) 7 (4-9) 0.30 
        Max R-Wave Lead avF 6 (IQR 4-12) 8 (IQR 1-7) 0.18 
T-wave Factors (mm)    
     Maximal T-wave amplitude any lead 6 (IQR 4-9) 5 (IQR 4-7) 0.03 
     Max T-wave Lead I (median) 2 (1-4) 1.5 (1-2.5) 0.005 
     Max T-wave Lead avF (median) 2 (1-3) 1.5 (1-2.5) 0.03 
     T-peak to T-end Lead V5 (median) 80 (IQR 60-80) 60 (IQR 40-80) 0.14 
R/T Ratios    
     Max R/T Any Lead (median) 2.5 (IQR 1.5-3.8) 2.7 (IQR 1.9-3.7) 0.6 
     R/T Lead I (median) 3.2 (IQR 2-5.25 ) 3.8 (2.2-8.9) 0.08 
    R/T Lead avF (median) 2.5 (IQR 1.3-5.1) 5 (IQR 3-8) 0.003 
    Max R/T <3 in any lead, n(%) 45(56%) 23(46%) 0.37 
    R/T <3 in avF, n(%) 43(53%) 11(22%) <0.001 
ESC 5 Year Risk 4.5 (IQR 2.9-7.4)    5.5 (IQR 3.2-8.7)            0.04 
     High Risk 26 (32%) 27 (54%) 0.02 
     Intermediate Risk     16 (20%) 8 (16%) 0.76 
     Low Risk 39 (48%) 15 (30%) 0.06 
Conventional Risk Factors ≥2 45 (56%) 36 (72%) 0.08 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 3. Predictors of Screening Failure 
Multivariable Analysis 
 OR 95% CI P-Value 
Age per year 0.97 0.95-0.99 0.03 
Maximal T-wave amplitude 
any lead per millimetre 
0.90 0.76-1.04 0.18 
T wave amplitude in Lead I  0.77 0.55-0.10 0.1 
R/T <3 in aVF 0.30 0.12-0.69 0.006 
Max LVOT velocity per mmHg 0.99 0.98-1.00 0.07 
    
    
 
 
 Figure Legends: 
 
Figure 1. Surface 3-lead ECG position for screening (A), with vectors between the three 
poles. Example of screening the screening template (B), with different profiles to fit the 
shape and size of the ECG. The template is used to assess the surface ECG for screening 
pass or fail (C), with the QRS complex required to cross the “peak-zone” but fit entirely within 
the shape of the template. 
 
 
Figure 2. Percentage and number of patients passing or failing screening in the supine, 
standing and exercise positions (A-C) as a proportion of total screened. Percentage of 
patients with 1, 2 or 3 qualifying vectors in those who passed, in each of the screening 
positions shown below (D-F). Lower panel shows the number of patients passing or failing 
in the alternate, secondary and primary vectors in each of the screening positions (G-I), with 
statistical significance between passing and failing shown above the bars. 
 
 
Figure 3. 3-Lead ECG factors influencing screening pass vs failure. Boxplots of differences 
in QRS amplitude (A), QRS width (B), T-wave amplitude (C) and R/T ratio (D) in the 3-Lead 
screening ECG, between patients who passed and failed screening. Statistical significance 
based on logistic regression is shown above each boxplot.   
 
 
 
 
